Natco intimates of launch of Glatiramer Acetate Injection in US

By its marketing partner Mylan

Natco Pharma announced that its marketing partner Mylan N.V., has launched in the US the first Glatiramer Acetate Injection 40 mg/mL for 3 times-a-week injection that is an AP rated substitutable generic version of Teva's Copaxone 40mg/mL, as well as Glatiramer Acetate Injection 20 mg/mL for once-daily injection, an AP rated, substitutable generic version of Teva's Copaxone 20mg/mL.

These products are indicated for the treatment of patients with relapsing forms of multiple sclerosis, a chronic inflammatory disease of the central nervous system. Shipments to customers have commenced.

Powered by Capital Market - Live News